Hepatoprotective activity of *Ficus semicordata* Buch.-Ham. ex Sm. leaves aqueous extract on D-galactosamine induced toxicity in HepG2 cell line

Shashi Gupta1*, Anagha Ranade2, Shivani Gayakwad2, Rabinarayan Acharya1 and Sharad Pawar2

1Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar 361008, India
2Regional Ayurveda Institute for Fundamental Research (RAIFR), Kothrud, Pune, Maharashtra 411038, India

Received 29 August 2019; Revised 12 September 2020

The leaves of *Ficus semicordata* Buch-Ham.ex Sm., locally in North India is referred to as *Bhumi udumbara* have been reported for their traditional use to cure jaundice and various liver ailments. Despite its extensive usage in northeastern states of India, there is a lack of scientific substantiation on the safety and pharmacotherapeutic efficacy. The present study was carried out to evaluate the hepatoprotective activity of *F. semicordata* (FS) leaves aqueous extract on HepG2 cell line to validate its ethnic claim in the management of liver disorders. D-galactosamine induced HepG2 cell toxicity model was used to evaluate its hepatoprotective activity. The cells were treated with different concentrations of aqueous extracts and dexamethasone as a standard. MTT assay was performed to determine the % inhibition of hepatotoxicity. The result indicates that the toxicity induced by D-galactosamine is reduced by FS aqueous extract group which is better when compared with the standard drug. This study revealed the hepatoprotective potential of *F. semicordata* on HepG2 cell line.

Keywords: D-galactosamine, Dexamethasone, *Ficus semicordata* Buch. Ham. ex Sm, Hepatoprotective, HepG2.

IPC code; Int. cl. (2015.01)- A61K 36/00, A61K 36/60, A61K 127/00, A61P 1/16

**Introduction**

*Ficus semicordata* Buch.-Ham. ex Sm., commonly known as drooping fig is a medium-sized evergreen tree, having oblong leaves with scabrid petioles. The tree typically lacks aerial roots. This plant with grey bark and pendulous branches bears pear-shaped figs. These figs often mature underground and hence the term *Bhumi udumbara*1,2. This plant is commonly found in India, Nepal, China, Bhutan and South-east Asian countries. It is distributed in forests ranging from Chenab to Myanmar3. The various parts of *F. semicordata* reported for medicinal uses are leaves, roots, bark, figs and latex and these are advocated in the management of liver ailments, jaundice, stomach disorders, wound, scabies, leprosy, indigestion and skin diseases4,5. The whole plant has been reported to possess steroids, terpenoids, flavonoids and glycosides6. Its leaves, in particular, possess catechins, quercetin, quercitrin and flavonoids6. It is also reported for anti-oxidant7, anti-bacterial activity8 and anti-diabetic activity9. Inspite of its extensive use in liver disorders and jaundice, the validated data for the claim is deficient. Hence, this study was planned to evaluate the hepatoprotective activity of *F. semicordata* leaf to validate its ethnic claim in the management of liver disorders.

**Material and Methods**

**Plant collection and identification**

The plant *F. semicordata*, growing naturally in Gandhamardana hills, Paikmal, Odisha, was identified by local Vaidya and taxonomist. The botanical name, *F. semicordata* was confirmed by studying the morphological characters in various floras. Sample specimen was authenticated by Dr Harisha C R, the head of pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar. Sample herbarium was deposited to institute’s pharmacognosy laboratory of Gujarat Ayurved University, Jamnagar.

**Sample preparation of plant extracts**

Aqueous extract of *F. semicordata* (FS) was prepared as per protocol mentioned in Ayurvedic Pharmacopoeia of India11. The leaves of FS were shade dried at room temperature. Dried leaves were pulverized to obtain a coarse powder. Five grams of coarse powder was subjected to extraction with

---

*Correspondent author
Email: shashi.gpt@gmail.com
100 mL of distilled water (six hours of shaking and 18 hours stand still method) to maximally yield soluble compounds. Later, this was filtered through Whatman filter paper, and the filtrate obtained was lyophilized using Lyophilizer (Labconco) at -50 °C and 0.020 mBarr pressure for 4-6 h to yield dried extract powder. The dried extract obtained was 0.7 g after lyophilization (14% yield) which was stored in an airtight container till further use.

Animal tissue culture

In this study, HepG2 cell line was procured from NCCS (National Centre of Cell Science), Pune. These cells were cultured and maintained in Minimum Essential Medium (MEM, Gibco-Invitrogen) media supplemented with 10% fetal bovine serum (FBS), Penicillin (100 U/mL) and Streptomycin (100 µg/mL) and incubated at 37 °C in a humidified incubator with 5% CO₂, 95% air. Cultures were regularly examined using an inverted microscope at 20X magnification and media changes were given every alternate day. Cells were grown till 70% confluency was achieved i.e.~1x10⁶/mL in T-25 tissue culture flask and then were sub-cultured as per the ATCC guidelines.

Cytotoxicity assay

Cytotoxicity assay was performed using MTT- [3-(4, 5 – dimethylthiazol–2-yl)-2,5-diphenyl tetrazolium bromide salt]. The cells were treated with different concentrations (50, 100, 150 and 200 µg/mL) of the plant extract and the absorbance was recorded using ELISA plate reader (EPOCH) at 540 nm².¹²

In-vitro hepatoprotective activity

Hepatotoxicity was induced in the cells using 15 mM of D-galactosamine as per the method described by Brindha et al., (2015)¹². The concentration of D-galactosamine was fixed after standardization. The test drug stock solution (2 mg/mL) was prepared by reconstituting the lyophilized FS in Milli-Q water during every experiment. The hepatotoxicity induced cells were treated with four different concentrations of the FS extract (FS1-50 µg/mL, FS2-100 µg/mL, FS3-150 µg/mL and FS4-200 µg/mL). Dexamethasone at 1.4 µM concentration was used as a standard drug against the D-galactosamine induced cells. When the D-galactosamine induced toxic cells were treated with various concentrations (50-200 µg/mL), it showed highly significant protection against toxicity as compared to D-galactosamine control. This protective effect was comparable to the control (cell blank) indicative of its ability to normalize the damaged cells. As seen in the graph the cell number has gradually increased as the concentration of the test drug increased.

Data analysis

Data obtained has been represented as mean±SD from triplicate per treatment group. The statistical analysis was done using ‘GraphPad Prism’statistical software. One-way analysis of variance (ANOVA) was used.

Results

Cytotoxicity assay

The cytotoxicity assay results are represented in Fig. 1 wherein HepG2 cells treated with various concentrations of test drug showed similar cell viability as in the cell blank. Thus, it is revealed that the test drug does not exhibit any significant toxicity up to 200 µg/mL. The evaluation of cytotoxicity was necessary for ruling out any hepatotoxicity of test drug itself.

Hepatoprotective activity

The results obtained are given in Table 1-3 and Fig 2. D-galactosamine control cells exhibited a significant reduction in cell number as compared to cell control, which can be reversed by the treatment with hepatoprotective agents. The inhibition of D-galactosamine induced cytotoxicity with dexamethasone treatment is suggestive of its ability to reverse the damage and protective role. When the D-galactosamine induced toxic cells were treated with various concentrations (50-200 µg/mL), it showed highly significant protection against toxicity as compared to D-galactosamine control. This protective effect was comparable to the control (cell blank) indicative of its ability to normalize the damaged cells. As seen in the graph the cell number has gradually increased as the concentration of the test drug increased.

Table 1 — Application of ANOVA showing statistical significance at \( p < 0.05 \)

<table>
<thead>
<tr>
<th></th>
<th>SS</th>
<th>Df</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>0.4922</td>
<td>6</td>
<td>0.08204</td>
</tr>
<tr>
<td>Residual</td>
<td>0.1312</td>
<td>21</td>
<td>0.006247</td>
</tr>
<tr>
<td>Total</td>
<td>0.6234</td>
<td>27</td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1 — HepG2 cells (Control) treated without D-galactosamine and test drugs (FS1-FS4)
drug increases which is suggestive of dose-dependent response. When the hepatotoxic cells were treated with 50 µg/mL, the cells showed inhibition similar to the standard drug Dexamethasone, and the test drug at 200 µg/mL concentration showed viable cell number which is closer to the control, thus we can say that the toxicity of D-galactosamine is inhibited at a greater extent. The maximum drug concentration was restricted to 200 µg/mL because it will not be feasible to prescribe the drug in human for achieving concentration above 200 µg/mL for bioavailability in the blood. This depicts the hepatoprotective role of FS against D-galactosamine induced toxicity in HepG2 cell line.

Table 2 — Application of Dunnett’s multiple comparison test showing statistical significance at $p < 0.05$ in control vs test drug groups (FS1-FS4)

<table>
<thead>
<tr>
<th>Dunnett's multiple comparison test</th>
<th>Mean Difference</th>
<th>q</th>
<th>Significant? $P &lt; 0.05$?</th>
<th>Summary</th>
<th>95% CI of diff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control vs Dgal</td>
<td>0.4080</td>
<td>7.300</td>
<td>Yes $***$</td>
<td>0.2520 to 0.5640</td>
<td></td>
</tr>
<tr>
<td>Control vs Dgal+dexa</td>
<td>0.2000</td>
<td>3.578</td>
<td>Yes $**$</td>
<td>0.04400 to 0.3560</td>
<td></td>
</tr>
<tr>
<td>Control vs FS1+Dgal</td>
<td>0.1925</td>
<td>3.444</td>
<td>Yes $*$</td>
<td>0.03650 to 0.3485</td>
<td></td>
</tr>
<tr>
<td>Control vs FS2+Dgal</td>
<td>0.08250</td>
<td>1.476</td>
<td>No ns</td>
<td>-0.07350 to 0.2385</td>
<td></td>
</tr>
<tr>
<td>Control vs FS3+Dgal</td>
<td>0.05875</td>
<td>1.051</td>
<td>No ns</td>
<td>-0.09725 to 0.2148</td>
<td></td>
</tr>
<tr>
<td>Control vs FS4+Dgal</td>
<td>0.01575</td>
<td>0.2818</td>
<td>No ns</td>
<td>-0.1403 to 0.1718</td>
<td></td>
</tr>
</tbody>
</table>

***- highly significant; **-significant

Table 3 — Application of Dunnett’s multiple comparison test showing statistical significance at $p < 0.05$ in D-galactosamine versus test drug groups (FS1-FS4)

<table>
<thead>
<tr>
<th>Dunnett's multiple comparison test</th>
<th>Mean difference</th>
<th>q</th>
<th>Significant? $P &lt; 0.05$?</th>
<th>Summary</th>
<th>95% CI of diff</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dgal vs Control</td>
<td>-0.4080</td>
<td>7.300</td>
<td>Yes $***$</td>
<td>-0.5640 to -0.2520</td>
<td></td>
</tr>
<tr>
<td>Dgal vs Dgal+dexa</td>
<td>-0.2080</td>
<td>3.722</td>
<td>Yes $**$</td>
<td>-0.3640 to -0.05200</td>
<td></td>
</tr>
<tr>
<td>Dgal vs FS1+Dgal</td>
<td>-0.2155</td>
<td>3.856</td>
<td>Yes $**$</td>
<td>-0.3715 to -0.05950</td>
<td></td>
</tr>
<tr>
<td>Dgal vs FS2+Dgal</td>
<td>-0.3255</td>
<td>5.824</td>
<td>Yes $***$</td>
<td>-0.4815 to -0.1695</td>
<td></td>
</tr>
<tr>
<td>Dgal vs FS3+Dgal</td>
<td>-0.3493</td>
<td>6.249</td>
<td>Yes $***$</td>
<td>-0.5053 to -0.1932</td>
<td></td>
</tr>
<tr>
<td>Dgal vs FS4+Dgal</td>
<td>-0.3923</td>
<td>7.018</td>
<td>Yes $***$</td>
<td>-0.5483 to -0.2362</td>
<td></td>
</tr>
</tbody>
</table>

***- highly significant; **-significant

Discussion

This study was planned to get an insight into the mode of action at the cellular level using in vitro cell-based model. Further, in the case of the hepatoprotective assay, D-galactosamine was chosen for inducing hepatotoxicity as this is a well-established hepatotoxin which generates damage analogous to viral hepatitis in humans regarding morphologic and functional characteristics of liver. A single dose can cause hepatocellular necrosis and fatty liver. The toxicity of D-galactosamine is mainly linked to the reduction of uridine pools that are associated with limited ribonucleic acid (RNA) and protein synthesis, thus disturbing hepatocellular function. Cholestasis caused by galactosamine is due to its damaging effect on bile ducts thereby reducing bile flow of bile salts, cholic acid and deoxycholic acid. It has been reported that Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats. Thus, it was used as the standard in the experiment which inhibits the D-galactosamine induced hepatotoxicity.

The test drug showed evidence of the hepatoprotective activity in a dose-dependent manner ranging from 50-200 µg/mL after which the effect may remain at pace with the untreated cells irrespective of dose. The leaves of FS have been reported to be rich in tannins, catechins and flavonoids namely quercetin. The hepatoprotective activity of FS against D-galactosamine induced toxicity in HepG2 cell line.
effect of FS may be due to its phytoconstituent quercetin a flavonoid and catechin which have antioxidant effect thereby preventing ROS formation and damage to hepatocyte as observed in the study\textsuperscript{19,20}. This hepatoprotective activity of FS leaves substantiates the ethnomedicinal claim in management of liver disorders and leaf decoction in combination with other plant extract is taken orally to get relief from jaundice\textsuperscript{21}. The jaundice is described in Ayurveda under Kamala which is mainly due to Pittaja vitiation. The liver is a mulasthana (primary site) of Raktajavyadhi (blood disorders). In a preliminary study in healthy volunteers, the Rasa of dried powder of leaves of FS is found to be Kashaya (astringent taste), madhura (sweet taste)\textsuperscript{22}. Kashaya rasa is reported to be Kledamedavishoshan (useful in dyslipidemia having be attributed in management of drug-induced be possibly correlated to the repair of liver tissue and can (~enhancing dermal health by removing toxins which reducing cholestasis. Also, it is tvakprasadana (scraping action) and hence could have a possible role in here can be correlated to epithelium of liver) which can substantiates the ethnomedicinal claim in management of liver disorders and leaf decoction in combination with other plant extract is taken orally to get relief from jaundice\textsuperscript{21}. The jaundice is described in Ayurveda under Kamala which is mainly due to Pittaja vitiation. The liver is a mulasthana (primary site) of Raktajavyadhi (blood disorders). In a preliminary study in healthy volunteers, the Rasa of dried powder of leaves of FS is found to be Kashaya (astringent taste), madhura (sweet taste)\textsuperscript{22}. Kashaya rasa is reported to be Kledamedavishoshan (useful in dyslipidemia having scraping action) and hence could have a possible role in reducing cholestasis. Also, it is tvakprasadana (~enhancing dermal health by removing toxins which here can be correlated to epithelium of liver) which can be possibly correlated to the repair of liver tissue and can be attributed in management of drug-induced liver injury\textsuperscript{23}.

Conclusion
The present study substantiates the hepatoprotective potential of aqueous extract of \textit{F. semicordata} leaves by alleviating the \textit{in vitro} D-galactosamine induced hepatotoxicity in HepG2 cells. \textit{In vitro} cell-based assay results observed in the present study must be correlated with suitable \textit{in vivo} model and could give better insights into the role of \textit{F. semicordata} in evaluating hepatoprotective activity clinically. There is a need for chemical evaluation to identify the active constituent, which is in process.

Acknowledgement
This study was fully funded by the Institute for Postgraduate Teaching and Research in Ayurved, GAU-Jamnagar from IMR project no. PGT/TRC/2019-20/986 sanctioned on 14/06/2019. The authors are thankful to DG, CCRAS (Ministry of AYUSH, Government of India), New Delhi for his support.

Conflict of interest
The authors declare no conflict of interest.

References


\textsuperscript{7} Gupta S, Acharya R, Antioxidant and nutritional evaluation of \textit{Bhu Udumbara} (\textit{Ficus semicordata} Buch.-Ham.ex Sm.) leaves and fruits: An extra pharmacopoeial drug of Ayurveda, \textit{Ayu}, 2019, 40(2), 120-126.


\textsuperscript{11} Anonymous, \textit{Ayurvedic Pharmacopoeia of India}, 1st edn, vol VII, (Dept. of Ayush, Govt. of India, New Delhi), 2008, 242.


\textsuperscript{18} Gabbia D, Pozzo L, Zigiotto G, Roverso M, Sacchi D, \textit{et al.}, Dexamethasone counteracts hepatic inflammation
and oxidative stress in cholestatic rats via CAR activation, *PloS one*, 2018, 13(9).


